World Health Organization, Geneva, Switzerland.
Fertil Steril. 1996 Apr;65(4):821-9.
To determine contraceptive efficacy of hormonally induced sperm suppression to severe oligozoospermia or azoospermia.
Prospective, noncomparative contraceptive efficacy study.
Multicenter study in 15 centers in nine countries.
Three hundred ninety-nine normal, healthy, fertile men requesting a male contraceptive method.
Weekly IM injection of 200 mg T enanthate.
Incidence of pregnancies in efficacy when couples relied on T injections alone for contraception.
Four pregnancies occurred during 49.5 person-years involving men with oligozoospermia (0.1 to 3 x 10(6)/mL) and none during 230.4 person-years in azoospermic men: pregnancy rates 8.1 (95 percent confidence interval [CI] 2.2 to 20.7) and 0.0 (95 percent CI, 0.0 to 1.6) per 100 person-years, respectively, or 1.4 (95 percent CI, 0.4 to 3.7) per 100 person-years for oligozoospermia and azoospermia (O to 3 x 10(6)/mL) combined. Pregnancy rates were related to sperm concentration. Inadequate suppression of spermatogenesis occurred in eight men and escape from suppression occurred in four. Discontinuations were due to personal reasons (50 men, cumulative annual life-table rate 12.2 percent [95 percent CI, 9.1 percent to 16.1 percent]) and dislike of the injection schedule (21 men, 5.1 percent [95 percent CI, 3.2 percent to 7.9 percent]). Thirty-five men discontinued for medical reasons (9.4 percent [95 percent CI, 6.7 percent to 13.2 percent]), with no serious treatment-related side effects. After stopping injections, sperm output recovered; additionally, fertility was demonstrated in 33 couples.
Suppression of spermatogenesis to azoospermia or severe oligozoospermia (< or = 3 x 10(6)/mL) induced by weekly T enanthate injections results in sustained, reversible contraception with good efficacy and minimal short-term side effects. New hormonal regimens with more convenient delivery and improved spermatogenic suppression would provide practical male contraception.
确定激素诱导精子抑制对严重少精子症或无精子症的避孕效果。
前瞻性、非对照避孕效果研究。
在9个国家的15个中心进行的多中心研究。
399名要求采用男性避孕方法的正常、健康、有生育能力的男性。
每周肌肉注射200mg庚酸睾酮。
夫妻仅依靠睾酮注射进行避孕时的妊娠发生率。
在49.5人年期间,少精子症(0.1至3×10⁶/mL)男性中有4例妊娠,无精子症男性在230.4人年期间无妊娠发生:每100人年的妊娠率分别为8.1(95%置信区间[CI]2.2至20.7)和0.0(95%CI,0.0至1.6),少精子症和无精子症(0至3×10⁶/mL)合并时为每100人年1.4(95%CI,0.4至3.7)。妊娠率与精子浓度有关。8名男性生精抑制不足且4名男性出现抑制逃逸。停药原因包括个人原因(50名男性,累积年生命表率12.2%[95%CI,9.1%至16.1%])和不喜欢注射方案(21名男性,5.1%[95%CI,3.2%至7.9%])。35名男性因医学原因停药(9.4%[95%CI,6.7%至13.2%]),无严重的治疗相关副作用。停止注射后,精子产量恢复;此外,33对夫妻恢复了生育能力。
每周注射庚酸睾酮诱导生精抑制至无精子症或严重少精子症(≤3×10⁶/mL)可实现持续、可逆的避孕,效果良好且短期副作用最小。采用更方便给药方式且改善生精抑制效果的新激素方案将为男性提供实用的避孕方法。